Lantheus Holdings downgraded by William Blair
$LNTH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
William Blair downgraded Lantheus Holdings from Outperform to Mkt Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2026 | Mkt Perform → Outperform | William Blair | |
| 12/12/2025 | $80.00 | Hold → Buy | Truist |
| 10/8/2025 | $77.00 | Buy → Neutral | Goldman |
| 8/12/2025 | $63.00 | Buy → Hold | Truist |
| 12/18/2024 | $143.00 | Buy | Goldman |
| 9/3/2024 | $175.00 | Buy | Redburn Atlantic |
| 7/10/2024 | $100.00 → $130.00 | Mkt Outperform | JMP Securities |
| 12/18/2023 | Outperform → Mkt Perform | William Blair |
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
4 - Lantheus Holdings, Inc. (0001521036) (Issuer)
HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026. "We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth," said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. "Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading radiopharmaceu
BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs). The FDA stated that the agency cannot approve the NDA by the Prescription Drug User Fee Act (PDUFA) action date of June 29, 2026, du
BEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 9. To access the live webcast of the presentations, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcasts will be available on the Company's website for at least 30 days followi
SD - Lantheus Holdings, Inc. (0001521036) (Filer)
SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
10-Q - Lantheus Holdings, Inc. (0001521036) (Filer)
4 - Lantheus Holdings, Inc. (0001521036) (Reporting)
William Blair upgraded Lantheus Holdings from Mkt Perform to Outperform
Truist upgraded Lantheus Holdings from Hold to Buy and set a new price target of $80.00
Goldman downgraded Lantheus Holdings from Buy to Neutral and set a new price target of $77.00
HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026. "We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth," said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. "Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading radiopharmaceu
BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025. "We are thrilled to welcome Dr. Dinkelborg and the entire Life Molecular team to Lantheus," said Brian Markison, CEO of Lantheus. "Ludger's proven leadership, scientific
BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob
SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)
SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)
Strong start to the year with worldwide revenue of $377.3 million in the first quarter 2026GAAP fully diluted earnings per share of $1.80, compared to $1.02 in the first quarter of 2025Adjusted fully diluted earnings per share of $1.46, compared to $1.53 in the first quarter of 2025FDA approves PYLARIFY TruVuTM (piflufolastat F18); phased geographic launch planned to begin in the fourth quarter of 2026FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003); expected to be the first radioequivalent for the treatment of gastroenteropancreatic neuroendocrine tumorsReaffirmed previously issued corporate guidance for full year 2026 revenue and adjusted fully diluted earnings per share BEDF
BEDFORD, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 7, 2026, to discuss its financial results and provide a business update for the first quarter of 2026. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 d
Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025Company announced today that it is sharpening its strategic focus to innovative radiodiagnostics and pursuing value‑maximizing alternatives for radiotherapeutic assets to support long-term growthCompany provides full year 2026 rev